...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: plenty of scenarios being put out there...

PVLee "....Those that have shares in Zenith right now are the ones who should be the beneficiaries. He believes this royalty stream will be a very significant number. For example, just from the China deal, there could be $300M in royalty stream. If things go as hoped in Resverlogix, this could be $1B/year. Divide that among the current shares outstanding (say 100M) and you've got a fair chunk of money coming your way every year. If I got $10/yr for every share I owned, I'd be a VERY happy camper...."

I don't know how you'd ever get to $10 /yr for every Zenith share. For example, if the net RVX revenue was $2 billion a year, I calculate $140 million a year in royalties to Zenith.

Share
New Message
Please login to post a reply